BioCentury | Mar 23, 2021
Finance

Crossovers invest ahead of pre-IPO round, as bispecifics play EpimAb readies to deploy $120M series C

...and Jefferies alum who joined Shanghai-based EpimAb Biotherapeutics Inc. last March from New York investment firm Millennium...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

...Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium...
BioCentury | Dec 16, 2020
Management Tracks

Sage puts pieces in place for growth as Greene, an architect of Alnylam, becomes CEO

...By Jeff Cranmer, Executive Editor Alnylam and Millennium...
...choice. Before Alnylam, Greene spent two years at Millennium Pharmaceuticals Inc....
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

...Coatue co-led the equity financing, which also saw participation from T. Rowe Price Associates, OrbiMed, Millennium...
BioCentury | Oct 3, 2020
Product Development

Departing Alnylam, Greene has messages for industry from company building to product pricing

...few RNAi platform biotechs. He came from Millennium Pharmaceuticals Inc....
...their own. When I got out to Millennium...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...amyloidosis (see “First RNAi Drug Approval” ). Prior to Alnylam, Greene spent two years at Millennium Pharmaceuticals Inc....
...granting Johnson & Johnson (NYSE:JNJ) ex-U.S. rights to the multiple myeloma drug. His time at Millennium...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

...also a co-founder. Lodish has helped found several biotechs, including Genzyme Inc., Axys Pharmaceuticals Inc., Millennium Pharmaceuticals Inc....
BioCentury | Jan 29, 2020
Company News

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

...before that CBO at Millennium Pharmaceuticals Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. At Infinity and Millennium...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...by medicine since the start of the century (see “It’s Been a Hell of a Millennium...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...few diseases where the outlook for patients is completely different from the start of the millennium...
Items per page:
1 - 10 of 1878
BioCentury | Mar 23, 2021
Finance

Crossovers invest ahead of pre-IPO round, as bispecifics play EpimAb readies to deploy $120M series C

...and Jefferies alum who joined Shanghai-based EpimAb Biotherapeutics Inc. last March from New York investment firm Millennium...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

...Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium...
BioCentury | Dec 16, 2020
Management Tracks

Sage puts pieces in place for growth as Greene, an architect of Alnylam, becomes CEO

...By Jeff Cranmer, Executive Editor Alnylam and Millennium...
...choice. Before Alnylam, Greene spent two years at Millennium Pharmaceuticals Inc....
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

...Coatue co-led the equity financing, which also saw participation from T. Rowe Price Associates, OrbiMed, Millennium...
BioCentury | Oct 3, 2020
Product Development

Departing Alnylam, Greene has messages for industry from company building to product pricing

...few RNAi platform biotechs. He came from Millennium Pharmaceuticals Inc....
...their own. When I got out to Millennium...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...amyloidosis (see “First RNAi Drug Approval” ). Prior to Alnylam, Greene spent two years at Millennium Pharmaceuticals Inc....
...granting Johnson & Johnson (NYSE:JNJ) ex-U.S. rights to the multiple myeloma drug. His time at Millennium...
BioCentury | Jul 1, 2020
Emerging Company Profile

With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

...also a co-founder. Lodish has helped found several biotechs, including Genzyme Inc., Axys Pharmaceuticals Inc., Millennium Pharmaceuticals Inc....
BioCentury | Jan 29, 2020
Company News

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

...before that CBO at Millennium Pharmaceuticals Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. At Infinity and Millennium...
BioCentury | Jan 1, 2020
Company News

Fewer FDA approvals in 2019, but a basket of firsts

...by medicine since the start of the century (see “It’s Been a Hell of a Millennium...
BioCentury | Dec 21, 2019
Product Development

It’s been a hell of a millennium -- and it’s just getting started

...few diseases where the outlook for patients is completely different from the start of the millennium...
Items per page:
1 - 10 of 1878